SNDX: Syndax Pharmaceuticals Inc. Stocks News on November 27, 2025

SNDX

Simply Wall St.

10 days ago

Syndax Pharmaceuticals (SNDX): Assessing Value After Revuforj FDA Expansion and Revenue Surge

SNDX

Insider Monkey

10 days ago

JPMorgan Reduces PT on Syndax Pharmaceuticals (SNDX) to $33, Maintains “Overweight” Rating

SNDX

GuruFocus.com

a month ago

Syndax Pharmaceuticals Inc (SNDX) Q3 2025 Earnings Report Preview: What To Expect

Syndax Announces Participation in November Investor Conferences

SNDX

GlobeNewswire

a month ago

Syndax Announces Participation in November Investor Conferences

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

SNDX

GlobeNewswire

a month ago

Syndax to Announce Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 3, 2025

Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision

SNDX

Insider Monkey

2 months ago

Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SNDX

GlobeNewswire

2 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Synopsys downgraded, Oracle upgraded: Wall Street's top analyst calls

SNDX

The Fly

3 months ago

Synopsys downgraded, Oracle upgraded: Wall Street's top analyst calls

SNDX

GlobeNewswire

3 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SNDX

MT Newswires

5 months ago

Syndax Gets US FDA Priority Review of Supplemental New Drug Application for Revuforj in Acute Myeloid Leukemia

$Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia$

SNDX

GlobeNewswire

5 months ago

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial

SNDX

Insider Monkey

5 months ago

Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial

Syndax reports publication of revumenib data from BEAT AML trial

SNDX

TipRanks

5 months ago

Syndax reports publication of revumenib data from BEAT AML trial

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

SNDX

GlobeNewswire

5 months ago

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

$Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025$

SNDX

GlobeNewswire

5 months ago

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

SNDX

GlobeNewswire

6 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation in June Investor Conferences

SNDX

GlobeNewswire

6 months ago

Syndax Announces Participation in June Investor Conferences

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

SNDX

GlobeNewswire

6 months ago

Syndax Announces Data Presentations at EHA 2025 Showcasing Revuforj® (revumenib) and Niktimvo™ (axatilimab-csfr)

SNDX

MT Newswires

6 months ago

Syndax Pharmaceuticals Appoints Nicholas Botwood Chief Medical Officer

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

SNDX

GlobeNewswire

6 months ago

Syndax Pharmaceuticals Appoints Dr. Nicholas Botwood as Head of Research and Development and Chief Medical Officer

SNDX

Zacks

7 months ago

Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High?

Syndax Announces Participation in May Investor Conferences

SNDX

GlobeNewswire

7 months ago

Syndax Announces Participation in May Investor Conferences

$Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood$

SNDX

GlobeNewswire

7 months ago

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood

SNDX

Thomson Reuters StreetEvents

7 months ago

Q1 2025 Syndax Pharmaceuticals Inc Earnings Call

SNDX

MT Newswires

7 months ago

Syndax Pharmaceuticals Q1 Loss Widens

SNDX

GuruFocus.com

7 months ago

Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ...

SNDX

Zacks

7 months ago

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates

SNDX

Associated Press Finance

7 months ago

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update

SNDX

GlobeNewswire

7 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SNDX

GuruFocus.com

7 months ago

Syndax Pharmaceuticals Inc (SNDX) Q1 2025: Everything You Need To Know Ahead Of Earnings

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

SNDX

GlobeNewswire

7 months ago

Syndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025

SNDX

GlobeNewswire

8 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

SNDX

GlobeNewswire

8 months ago

Syndax Announces Participation at the Stifel 2025 Virtual Targeted Oncology Forum

SNDX

GlobeNewswire

9 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SNDX

GuruFocus.com

9 months ago

Syndax Pharmaceuticals Inc (SNDX) Q4 2024 Earnings Call Highlights: Strong Product Launch and ...

SNDX

MT Newswires

9 months ago

B. Riley Cuts Price Target on Syndax Pharmaceuticals to $29 From $36, Keeps Buy Rating

SNDX

Zacks

9 months ago

Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Lags Revenue Estimates

SNDX

MT Newswires

9 months ago

Syndax Pharmaceuticals Q4 Loss Widens

SNDX

Associated Press Finance

9 months ago

Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

SNDX

GuruFocus.com

9 months ago

Earnings To Watch: Syndax Pharmaceuticals Inc (SNDX) Reports Q4 2024 Result

Syndax Announces Participation in March Investor Conferences

SNDX

GlobeNewswire

9 months ago

Syndax Announces Participation in March Investor Conferences

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

SNDX

GlobeNewswire

9 months ago

Syndax to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call and Webcast on March 3, 2025

SNDX

Simply Wall St.

9 months ago

Here's Why We're Watching Syndax Pharmaceuticals' (NASDAQ:SNDX) Cash Burn Situation

SNDX

PR Newswire

10 months ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation in February Investor Conferences

SNDX

PR Newswire

10 months ago

Syndax Announces Participation in February Investor Conferences

SNDX

MT Newswires

10 months ago

Incyte, Syndax Receive FDA Approval for Niktimvo to Treat Chronic Graft-Versus-Host Disease

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

SNDX

PR Newswire

10 months ago

Incyte and Syndax Announce U.S. Food and Drug Administration (FDA) Approval of Niktimvo™ (axatilimab-csfr) 9 mg and 22 mg Vial Sizes

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

SNDX

PR Newswire

10 months ago

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference

SNDX

Simply Wall St.

a year ago

Investing in Syndax Pharmaceuticals (NASDAQ:SNDX) five years ago would have delivered you a 53% gain

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

SNDX

PR Newswire

a year ago

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference

SNDX

PR Newswire

a year ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

$Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial$

SNDX

PR Newswire

a year ago

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

SNDX

PR Newswire

a year ago

Syndax Presents Positive Revuforj® (revumenib) Data in Acute Leukemias from Multiple Trials, Including the SAVE Combination and AUGMENT-101 Trials, at 66th ASH Annual Meeting

SNDX

Insider Monkey

a year ago

Why Is Syndax Pharmaceuticals, Inc. (SNDX) Among the Best Small-Cap Biotech Stocks With Massive Potential According to Hedge Funds?

SNDX

PR Newswire

a year ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference

SNDX

PR Newswire

a year ago

Syndax Announces Participation at the Citi 2024 Global Healthcare Conference

Syndax secures FDA OK for new kind of leukemia drug

SNDX

BioPharma Dive

a year ago

Syndax secures FDA OK for new kind of leukemia drug

FDA approves Syndax’s Revuforj to treat leukaemia

SNDX

Pharmaceutical Technology

a year ago

FDA approves Syndax’s Revuforj to treat leukaemia

$Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation$

SNDX

PR Newswire

a year ago

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

SNDX

Zacks

a year ago

Biotech Stock Roundup: NVAX Q3 Results, SNDX Down on AML Data, RNA Surges on Study Data

Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint

SNDX

Pharmaceutical Technology

a year ago

Syndax’s stock sinks by 25% despite AML trial meeting primary endpoint

Syndax’s revumenib meets primary results in AML trial

SNDX

TipRanks

a year ago

Syndax’s revumenib meets primary results in AML trial

Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer

SNDX

Benzinga

a year ago

Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage Study Of Revumenib In Form Of Blood Cancer

$Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib$

SNDX

PR Newswire

a year ago

Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib

SNDX

Simply Wall St.

a year ago

Analysts Are Updating Their Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Estimates After Its Third-Quarter Results

SNDX

Thomson Reuters StreetEvents

a year ago

Q3 2024 Royalty Pharma PLC Earnings Call

SNDX

Thomson Reuters StreetEvents

a year ago

Q3 2024 Syndax Pharmaceuticals Inc Earnings Call

Moderna said to shuffle sales leadership; Vertex records first Casgevy sale

SNDX

BioPharma Dive

a year ago

Moderna said to shuffle sales leadership; Vertex records first Casgevy sale

SNDX

GuruFocus.com

a year ago

Syndax Pharmaceuticals Inc (SNDX) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

SNDX

Zacks

a year ago

Syndax Pharmaceuticals (SNDX) Reports Q3 Loss, Tops Revenue Estimates

SNDX

Associated Press Finance

a year ago

Syndax: Q3 Earnings Snapshot

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update

SNDX

PR Newswire

a year ago

Syndax Reports Third Quarter 2024 Financial Results and Provides Business Update

Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024

SNDX

PR Newswire

a year ago

Syndax to Host ASH Investor Event in Person and via Webcast on December 9, 2024

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting

SNDX

PR Newswire

a year ago

Syndax Announces Revumenib Abstracts to Be Presented at the 66th ASH Annual Meeting

Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

SNDX

PR Newswire

a year ago

Syndax Announces New Data from Secondary Analysis of the Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease to Be Presented at 66th ASH Annual Meeting

Syndax agrees funding with Royalty Pharma for Niktimvo US sales

SNDX

Pharmaceutical Technology

a year ago

Syndax agrees funding with Royalty Pharma for Niktimvo US sales

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

SNDX

PR Newswire

a year ago

Syndax Pharmaceuticals and Royalty Pharma Enter into $350 Million Royalty Funding Agreement for Niktimvo™

SNDX

PR Newswire

a year ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SNDX

PR Newswire

a year ago

Syndax Announces Participation in November Investor Conferences

Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024

SNDX

PR Newswire

a year ago

Syndax to Announce Third Quarter 2024 Financial Results and Host Conference Call and Webcast on November 5, 2024

SNDX

MT Newswires

a year ago

UBS Initiates Syndax Pharmaceuticals With Buy Rating, $37 Price Target

State Street Corp's Strategic Acquisition in Syndax Pharmaceuticals

SNDX

GuruFocus.com

a year ago

State Street Corp's Strategic Acquisition in Syndax Pharmaceuticals

SNDX

GuruFocus.com

a year ago

Syndax Pharmaceuticals Inc (SNDX) Q2 2024 Earnings Call Highlights: Strategic Advances and ...

SNDX

PR Newswire

a year ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

SNDX

PR Newswire

a year ago

Incyte and Syndax Announce New England Journal of Medicine Publication of Data from Pivotal AGAVE-201 Trial of Niktimvo™ (axatilimab-csfr) in Chronic Graft-Versus-Host Disease

SNDX

Simply Wall St.

a year ago

We Think Syndax Pharmaceuticals (NASDAQ:SNDX) Needs To Drive Business Growth Carefully

SNDX

PR Newswire

a year ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SNDX

Insider Monkey

a year ago

Syndax Pharmaceuticals, Inc. (SNDX): This Small-Cap Healthcare Stock Is A Good Buy Right Now

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug

SNDX

Zacks

a year ago

Incyte (INCY) Announces Data on Monjuvi, FDA Approval for GVHD Drug

FDA greenlights Incyte and Syndax’s GvHD drug Niktimvo

SNDX

Pharmaceutical Technology

a year ago

FDA greenlights Incyte and Syndax’s GvHD drug Niktimvo

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication

SNDX

Benzinga

a year ago

FDA Approves Incyte/Syndax Partnered Drug For Chronic Graft-Versus-Host Disease, A Post-Transplant Complication

SNDX

MT Newswires

a year ago

Sector Update: Health Care Stocks Flat to Higher Premarket Thursday

SNDX

MT Newswires

a year ago

Sector Update: Health Care

SNDX

MT Newswires

a year ago

Incyte, Syndax Pharmaceuticals Get FDA Approval for Graft-Versus-Host Treatment

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

SNDX

Business Wire

a year ago

Incyte and Syndax Announce U.S. FDA Approval of Niktimvo™ (axatilimab-csfr) for the Treatment of Chronic Graft-Versus-Host Disease (GVHD)

$Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia$

SNDX

PR Newswire

a year ago

Syndax Announces Publication in the Journal of Clinical Oncology of Data from the Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

SNDX

PR Newswire

a year ago

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

SNDX

Simply Wall St.

a year ago

Latest Syndax Pharmaceuticals Inc. (SNDX) News on November 27, 2025

Share on Social Networks: